Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAK Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction
NCT03681275Phase 2Active, not recruiting
- Sponsor
- Stanford University
- Start
- Sep 2019
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tofacitinib oral solution in diaphragm dysfunction (2 arms), sponsored by Stanford University. Primary endpoint: Prevention of ventilator-induced diaphragm dysfunction by JAK inhibition. Started Sep 2019; status: active, not recruiting.
02
Drugs
tofacitinib oral solution
03
Conditions
diaphragm dysfunction
Beyond the preview
Go deeper on NCT03681275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03681275.